Prev Med by Miller, Jacqueline W. et al.
Physicians' beliefs about effectiveness of cancer screening 
tests: A national survey of family physicians, general internists, 
and obstetrician–gynecologists
Jacqueline W. Millera,*, Laura-Mae Baldwinb, Barbara Matthewsb, Katrina F. Triversa, C. 
Holly Andrillab, Denise Lishnerb, and Barbara A. Goffc
aDivision of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, 
GA, USA
bDepartment of Family Medicine, University of Washington, Seattle, WA, USA
cDepartment of Obstetrics and Gynecology, University of Washington, Seattle, WA, USA
Abstract
Objective—To study physicians' beliefs about the effectiveness of different tests for cancer 
screening.
Methods—Data were examined from the Women's Health Survey of 1574 Family Medicine, 
Internal Medicine, and Obstetrics–Gynecology physicians to questions about their level of 
agreement about the clinical effectiveness of different tests for breast, cervical, ovarian, and 
colorectal cancer screening among average risk women. Data were weighted to the U.S. physician 
population based on the American Medical Association Masterfile. Multivariable logistic 
regression identified physician and practice characteristics significantly associated with 
physicians' beliefs.
Results—There were 1574 respondents, representing a 62% response rate. The majority of 
physicians agreed with the effectiveness of mammography for women aged 50–69 years, Pap tests 
for women aged 21–65 years, and colonoscopy for individuals aged ≥50 years. A substantial 
proportion of physicians believed that nonrecommended tests were effective for screening (e.g., 
34.4% for breast MRI and 69.1% for annual pelvic exam). Physicians typically listed their 
respective specialty organizations as a top influential organization for screening recommendations.
Conclusions—There were several substantial inconsistencies between physician beliefs in the 
effectiveness of cancer screening tests and the actual evidence of these tests' effectiveness which 
can lead both to underuse and overuse of cancer screening tests.
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Introduction
Prevention and early detection of cancer are the most effective ways to decrease cancer 
morbidity and mortality. Through appropriate cancer screening, some cancers may be 
prevented or detected early when treatment is most effective (Nelson et al., 2009; Preventive 
Services, 2008; Preventive Services Task Force (USPSTF), 1996; American College of 
Obstetricians and Gynecologists Committee on Practice Bulletins—Gynecology, 2009 Dec). 
However, not all cancers have effective screening tests, and symptom recognition may be 
the key to detecting some cancers early. (Baldwin et al., 2012a; Devlin et al., 2010; Goff et 
al., 2007; Meissner et al., 2010; Ryerson et al., 2007; Yabroff et al., 2011a) Despite these 
facts, there is a wide variation in cancer screening practices across the United States, 
resulting in both overscreening and underscreening.
Studies evaluating screening practices have shown that physicians' recommendations, along 
with patient barriers and beliefs, are important determinants of cancer screening (Coughlin 
et al., 2005; Goldzweig et al., 2004; Gorin et al., 2007; Najem et al., 1996; Ramirez et al., 
2009; Rauscher et al., 2005; Schueler et al., 2008; Teng et al., 2006; Wong et al., 2010). 
While many studies have focused on physician knowledge, patient characteristics, and use 
of reminder systems to encourage screening, (Lester et al., 2009; Nadel et al., 2010; Nichols 
et al., 2009; Saraiya et al., 2010; Sequist et al., 2009; Werny et al., 2008; Yabroff et al., 
2011b) only a few older studies have examined physician beliefs about the effectiveness of 
tests for cancer screening, and these studies have typically occurred in small, defined 
geographical areas (Clasen et al., 1994; Cummings et al., 1984).
In an attempt to minimize variation and increase the use of appropriate cancer screening 
tests, evidence-based guidelines targeted to health care providers have been developed. This 
is an important strategy, as patients have consistently reported that a physician 
recommendation is one of the most important influences on their decision to complete 
cancer screening tests (Goldzweig et al., 2004; Schueler et al., 2008). A previous review 
reported that physicians' lack of agreement with recommendations serves as a barrier to 
guideline adherence (Cabana et al., 1999 Oct 20). Understanding physician beliefs about the 
effectiveness of cancer screening tests is an essential step in ensuring that patients receive 
evidence-based cancer screening.
In this study, data from Women's Health Survey sent to a nationally representative sample of 
family medicine (FM), general internal medicine (IM), and obstetrics–gynecology (Ob/Gyn) 
physicians were used to examine their beliefs about the effectiveness of different tests to 
screen for breast, cervical, colorectal (CRC), and ovarian cancer among average risk 
women. The findings from this study can help guide the development of interventions to 
educate physicians about the effectiveness of cancer screening tests and ultimately to 
improve the appropriate use of these tests.
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The study sample included 3200 U.S. physicians aged 64 years and younger practicing in 
office or hospital settings. Equal numbers of FM, IM, and Ob/Gyn physicians were selected 
by stratified random sampling from the American Medical Association (AMA) Physician 
Masterfile. Physicians aged 65 years and older were excluded to ensure a sample of 
physicians most likely to be in active clinical practice.
Survey instrument and administration
A 12-page mail survey examining physicians' agreement with clinical effectiveness of 
cancer screening tests for breast, cervical, colorectal, and ovarian cancers; reported care for 
women's health through vignettes about preventive care services, specialty referral, and 
patient risk assessment; attitudes towards taking risks; sources of information about cancer 
screening; and personal cancer experience was administered November 2008–January 2009. 
The questionnaire also captured physician demographics and practice characteristics. 
Detailed descriptions of the survey and its administration have previously been reported 
(Baldwin et al., 2012b; Goff et al., 2011a,b; Trivers et al., 2011). Institutional Review Board 
approval was obtained from the University of Washington and the Centers for Disease 
Control and Prevention.
Variables of interest
For this study, we examined the question that asked physicians about their level of 
agreement (strongly disagree, disagree, agree, and strongly agree) with statements that 
various tests were clinically effective in screening for breast, cervical, ovarian, and CRC in 
the average risk population. We defined belief in the clinical effectiveness of a test for 
cancer screening if the physician responded “agree” or “strongly agree” with the statement. 
The tests for breast cancer screening included mammography for women aged 40–49 years, 
mammography for women aged 50–69 years, breast magnetic resonance imaging (MRI), 
and clinical breast examination (CBE); cervical cancer screening included human 
papillomavirus (HPV) test without Papanicolaou (Pap) test for women aged 30–65 years 
(primary HPV screening) and Pap test for those aged 21–65 years; ovarian cancer screening 
included cancer antigen 125 (CA-125) testing, transvaginal ultrasound (TVU), and annual 
pelvic examination; and CRC screening included colonoscopy, computed tomography (CT) 
colonography, sigmoidoscopy, and take-home fecal occult blood test (FOBT).
Physician characteristics (age, specialty, sex, board certification, years in practice, group 
versus solo practice, weekly average number of patients, involvement in clinical teaching, 
personal experience with cancer, geographic location, census division, level of risk-taking, 
and fear of malpractice) were examined as factors that might predict physicians' belief in the 
effectiveness of each test for cancer screening. Since beliefs may be related to where and 
from whom a physician receives cancer screening information, we also assessed which 
professional organizations influenced their cancer screening recommendations.
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Initial physician exclusions from the 3200 study sample included 33 duplicates; 95 
undeliverables; 19 retired, disabled, or deceased; and 11 not practicing or on leave. Of the 
remaining 3042 physicians who were mailed surveys, 1878 (61.7%) responded. Further 
exclusions were 200 respondents reporting not providing outpatient care to women; 71 
working in settings not providing outpatient/primary care (e.g., emergency rooms); 10 
reporting specialties other than FM, IM, and Ob/Gyn; and 23 in residency or fellowship 
training. The final sample included 1574 respondents. Responses were weighted to their 
representative number in the practicing U.S. physician population by medical specialty using 
AMA Physician Masterfile counts proportionately.
Stepwise multivariable logistic regression analysis identified the physician and practice 
characteristics that were independently and significantly associated with belief in the 
effectiveness of each test for cancer screening at the p ≤ 0.05 level. The characteristics 
entered into the regression analysis were those significantly associated with belief in the test 
effectiveness for cancer screening in an unadjusted analysis. Only organizations that make 
recommendations on a specific type of cancer were included in that regression model, such 
as the use of the U.S. Preventive Services Task Force (USPSTF) and the American Cancer 
Society (ACS) for all four cancers and use of the American Congress of Obstetricians and 
Gynecologists (ACOG) for breast, cervical, and ovarian cancers. All analyses were 
conducted using SUDAAN 10.0 (RTI International, Research Triangle Park, NC). Because 
belief in the effectiveness of cancer screening tests was a common outcome, risk ratios 
within SUDAAN based on predicted marginals were calculated (Bieler et al., 2010).
Results
In the weighted study sample, 41.5% were FM, 41.0% IM, and 17.5% Ob/Gyn physicians 
(Table 1). Almost half (42.7%) of physicians were aged 50–64 years, 71.1% were 
Caucasian, and 40.4% were female. In addition, 91.6% were board certified and 82.0% had 
been in practice for more than 10 years.
Influential organizations for cancer screening recommendations
Most physicians ranked their respective specialty professional organization as one of the top 
organizations that influenced their cancer screening recommendations (Table 2). Across all 
three specialties, the majority of physicians reported the ACS as a top influential 
organization. More than half of FM and IM physicians reported the USPSTF, and almost 
half of the Ob/Gyn physicians ranked the National Institutes of Health/National Cancer 
Institute (NCI) as one of their top influential organizations.
Breast cancer
For breast cancer screening, half of the physicians strongly agreed and slightly less than half 
agreed that mammography is an effective test for women aged 40–49 years (Table 3). For 
women aged 50–69 years, 81.7% of physicians strongly agreed that mammography is an 
effective screening test for breast cancer. Large percentages of physicians also either 
strongly agreed (40.0%) or agreed (45.4%) that the CBE is an effective screening test. Over 
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one-third of physicians agreed that MRI is an effective screening test for average risk 
women.
In the adjusted analysis (Table 4), physicians who listed the ACS as one of their top 
influential organizations were significantly more likely to believe that mammography is an 
effective cancer screening test for women aged 40–49 years, whereas physicians listing the 
USPSTF as a top influential organization were less likely to believe this test is effective. 
Physicians who reported a personal cancer experience were less likely to believe that 
mammography is effective for women aged 50–69 years. Physicians who were involved in 
clinical teaching or who listed USPSTF as an influential organization were significantly less 
likely to believe that the CBE is an effective screening test.
Cervical cancer
Physicians strongly agreed (70.3%) or agreed (29.1%) that Pap testing is effective as a 
cancer screening test for women aged 21–65 years. Almost half of the physicians (48.0%) 
agreed or strongly agreed that the HPV test alone is effective for cervical cancer screening 
(Table 3). In the adjusted analysis (Table 4), FM and IM physicians were significantly less 
likely to believe that the HPV test alone is effective compared with Ob/Gyn physicians.
Ovarian cancer
Only 17.6% of physicians agreed or strongly agreed that CA-125 is an effective test and 
30.3% of physicians agreed or strongly agreed that TVU is an effective test for ovarian 
cancer screening in the average risk population (Table 3). For the annual pelvic exam, 
30.0% of physicians strongly agreed and 39.1% agreed that it is an effective ovarian cancer 
screening test.
In adjusted analysis (Table 4), physicians in practice for ≥20 years and FM and IM 
physicians were more likely to believe CA-125 is an effective ovarian cancer screening. In 
contrast, physicians who were board certified, in group practice, had a personal experience 
with cancer and listed USPSTF as a top influential organization were less likely to believe 
that CA-125 is an effective cancer screening test. Physicians who agreed that TVU is an 
effective screening test were more likely to have been in practice ≥20 years versus 0–10 
years, to be an IM physician versus an Ob/Gyn physician, and to list the NCI as an 
influential organization. Physicians who were board certified, in group practice, and listed 
the USPSTF as a top influential organization were less likely to agree that TVU is an 
effective screening test. As with CA-125, FM and IM physicians were more likely to believe 
in annual pelvic exam as an effective screening test. Physicians less likely to believe that 
pelvic exam is effective were those listing USPSTF as a top influential organization, in 
group versus solo practice, and involved in clinical teaching.
Colorectal cancer
While 81.8% of physicians strongly agreed that colonoscopy is an effective screening test 
for CRC, only 24.0% strongly agreed that FOBT is effective (Table 3). Over a third (37.6%) 
of physicians agreed or strongly agreed that CT colonography is effective for CRC 
screening. In adjusted analysis (Table 4), no physician characteristics were significantly 
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associated with belief that either colonoscopy or CT colonography are effective CRC 
screening tests. IM physicians were less likely than Ob/Gyn physicians to believe that 
flexible sigmoidoscopy is effective. Those listing USPSTF as a top influential organization 
were more likely to believe that flexible sigmoidoscopy is an effective screening test.
Discussion
Just as cancer screening practices vary widely across the United States, so do physician 
beliefs in the effectiveness of cancer screening tests. Physicians believe that mammography 
for women aged 50–59 years and Pap testing for women aged 21–65 years are effective 
cancer screening tests, consistent with the recommendations of the USPSTF, ACS and 
ACOG. Interestingly, only half of the physicians believed that mammography is effective 
for women aged 40–49 years, which may be related to the controversy that has persisted for 
many years about the net benefits of mammography among this age group. However, at the 
time of the survey, the USPSTF, ACS and ACOG all recommended routine mammography 
screening for this age group. Since the survey, the USPSTF has changed its 
recommendations and no longer recommends routine mammography for this age group. Our 
finding is consistent with another study by Meissner et al. in which fewer primary care 
physicians reported that mammography was very effective for women aged 40–49 years 
compared to women aged ≥50 years (Meissner et al., 2011).
Although no organizations recommend MRI for breast cancer screening among average risk 
women, over one third of physicians believed that this test is effective. This finding is 
concerning because there is no evidence documenting its effectiveness as a screening test 
among average risk women. MRI has higher sensitivity than mammography, but a lower 
specificity and a higher false positive rate (Brennan et al., 2009). Similarly, it is concerning 
that over one quarter to half of physicians agreed that CA-125, TVU and pelvic exams are 
effective for ovarian cancer screening among average risk women, even though no 
organizations recommend this nor is there any evidence of their effectiveness (Smith et al., 
2011; U.S. Preventive Services Task Force, 2004).
For cervical cancer screening, nearly half of physicians agreed that HPV testing alone is 
effective, though not currently recommended. Ob/Gyn physicians were more likely than 
either FM or IM physicians to believe that HPV testing alone is effective. This may be due 
to their understanding of the relationship between HPV and cervical cancer, and the 
sensitivity of HPV testing (Carter et al., 2011 Apr; Trottier and Franco, 2006).
For CRC screening, our findings were similar to previous published reports (Klabunde et al., 
2009). Compared to colonoscopy, smaller percentages of physicians believed that 
sigmoidoscopy and FOBT are effective screening tests, even though these are the only CRC 
screening tests proven effective by randomized controlled trials. These FOBT findings are 
very similar to previous studies in which few physicians felt that FOBT was an effective 
screening test (Hawley et al., 2001; Klabunde et al., 2009; Nadel et al., 2005). Beliefs 
regarding some CRC screening tests may reflect confusion because there are multiple 
recommended tests with varying screening intervals. Also, some physicians' 
recommendations regarding specific CRC tests may be influenced by reimbursement 
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policies and rates from insurance providers. This may in turn influence their beliefs 
(Guessous et al., 2010; Palmer et al., 2010 Nov 24).
As expected, physicians frequently reported their own specialty professional organizations 
among the top organizations that influenced their cancer screening recommendations. The 
use of specialty specific professional organizations is not unexpected given that these are the 
certification organizations that typically provide practice guidelines for each medical 
specialty and play an important role in continuing medical education (Pellegrino and 
Relman, 1999). This finding is very similar to that of a study showing that the majority of 
FM and Ob/Gyn physicians rated guidelines for breast and cervical cancer screening from 
their own professional society as very influential (Han et al., 2011). This suggests that 
promoting the use of evidence-based recommendations through professional organizations 
could potentially be important interventions to improve appropriate use of screening tests.
Our study has several limitations. First, this study depends on self-reported responses to the 
level of agreement with effectiveness of specific screening tests. These responses could be 
influenced by the desire to report expected findings. Also, belief in test effectiveness is not 
necessarily related to the physicians' understanding and use of national recommendations, 
but may be related to the physician's personal practice style, test performance, or personal 
medical history. Finally, the survey did not define “effectiveness”, therefore physicians may 
have different interpretations regarding decreasing mortality, improving 5-year survival, or 
preventing disease. Despite these limitations, this study has a strong response rate and is 
nationally representative of primary care physicians across the United States.
Conclusions
Physician beliefs about the effectiveness of specific screening tests may impact their 
recommendation or performance of these tests. We have demonstrated several substantial 
inconsistencies between physician beliefs in the effectiveness of cancer screening tests and 
the actual evidence of these tests' effectiveness. These inconsistencies can lead both to 
overuse of cancer screening resources and underdiagnosis of some cancers. Since physicians 
are typically influenced by their specialty organizations, collaborating with professional 
organizations on targeted intervention efforts can enhance physician education and help 
ensure that practice patterns match evidence-based recommendations regarding cancer 
screening. Understanding physician's beliefs, practices, and modes of learning are important 
for determining which intervention efforts and venues will be most effective in increasing 
evidence-based cancer screening practice.
Acknowledgments
The authors would like to acknowledge A. Blythe Ryerson MPH from the CDC for her early contributions to the 
development of the study's methods and Gilmore Research Group in Seattle, Washington for conducting the survey.
Funding/support
This project was funded by the Centers for Disease Control and Prevention (CDC) through the University of 
Washington Health Promotion Research Centers Cooperative Agreement U48DP001911, and through the Alliance 
for Reducing Cancer, Northwest (ARC NW), funded by both the Centers for Disease Control and Prevention 
(CDC) and the National Cancer Institute (NCI).
Miller et al. Page 7














American College of Obstetricians and Gynecologists Committee on Practice Bulletins—Gynecology. 
ACOG practice bulletin no. 109: cervical cytology screening. Obstet. Gynecol. 2009 Decc;114(6):
1409–1420. [PubMed: 20134296] 
Baldwin LM, Trivers KF, Matthews B, et al. Ovarian cancer screening: are U.S. physicians adhering to 
evidence-based recommendations? Ann. Intern. Med. 2012a; 156(3):182–194. [PubMed: 22312138] 
Baldwin LM, Trivers KF, Matthews B, et al. Vignette-based study of ovarian cancer screening: do 
U.S. physicians report adhering to evidence-based recommendations? Ann. Intern. Med. 2012b; 
156(3):182–194. [PubMed: 22312138] 
Bieler GS, Brown GG, Williams RL, Brogan DJ. Estimating model-adjusted risks, risk differences, 
and risk ratios from complex survey data. Am. J. Epidemiol. 2010; 171(5):618–623. [PubMed: 
20133516] 
Brennan M, Spillane A, Houssami N. The role of breast MRI in clinical practice. Aust. Fam. 
Physician. 2009; 38(7):513–519. [PubMed: 19575070] 
Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical practice guidelines? A 
framework for improvement. JAMA. 1999 Oct 20; 282(15):1458–1465. [PubMed: 10535437] 
Carter JR, Ding Z, Rose BR. HPV infection and cervical disease: a review. Aust. N. Z. J. Obstet. 
Gynaecol. 2011 Aprr;51(2):103–108. [PubMed: 21466509] 
Clasen CM, Vernon SW, Mullen PD, Jackson GL. A survey of physician beliefs and self-reported 
practices concerning screening for early detection of cancer. Soc. Sci. Med. 1994; 39(6):841–849. 
[PubMed: 7973880] 
Coughlin SS, Breslau ES, Thompson T, Benard VB. Physician recommendation for papanicolaou 
testing among U.S. women, 2000. Cancer Epidemiol. Biomarkers Prev. 2005; 14(5):1143–1148. 
[PubMed: 15894664] 
Cummings KM, Jaen CR, Funch DP. Family physicians' beliefs about screening for colorectal cancer 
using the stool guaiac slide test. Public Health Rep. 1984; 99(3):307–312. [PubMed: 6429730] 
Devlin SM, Diehr PH, Andersen MR, Goff BA, Tyree PT, Lafferty WE. Identification of ovarian 
cancer symptoms in health insurance claims data. J. Women's Health. 2010; 19(3):381–389.
Goff BA, Mandel LS, Drescher CW, et al. Development of an ovarian cancer symptom index: 
possibilities for earlier detection. Cancer. 2007; 109(2):221–227. [PubMed: 17154394] 
Goff B, Miller JW, Matthews B, et al. Involvement of gynecologic oncologists in the treatment of 
patients with a suspicious ovarian mass. Obstet. Gynecol. 2011a; 118(4):854–862. [PubMed: 
21934449] 
Goff BA, Matthews B, Andrilla CHA, et al. How are symptoms of ovarian cancer managed? A study 
of primary care physicians. Cancer. 2011b; 117(19):4414–4423. [PubMed: 21413001] 
Goldzweig CL, Parkerton PH, Washington DL, Lanto AB, Yano EM. Primary care practice and 
facility quality orientation: influence on breast and cervical cancer screening rates. Am. J. Manag. 
Care. 2004; 10(4):265–272. [PubMed: 15124503] 
Gorin SS, Ashford AR, Lantigua R, et al. Intraurban influences on physician colorectal cancer 
screening practices. J. Natl. Med. Assoc. 2007; 99(12):1371–1380. [PubMed: 18229773] 
Guessous I, Dash C, Lapin P, Doroshenk M, Smith RA, Klabunde CN. National colorectal cancer 
roundtable screening among the 65 plus task group. Colorectal cancer screening barriers and 
facilitators in older persons. Prev. Med. 2010; 5(1–2):3–10. [PubMed: 20006644] 
Han PK, Klabunde CN, Breen N, et al. Multiple clinical practice guidelines for breast and cervical 
cancer screening: perceptions of US primary care physicians. Med. Care. 2011; 49(2):139–148. 
[PubMed: 21206294] 
Hawley ST, Levin B, Vernon SW. Colorectal cancer screening by primary care physicians in two 
medical care organizations. Cancer Detect. Prev. 2001; 25(3):309–318. [PubMed: 11425273] 
Klabunde CN, Lanier D, Nadel MR, McLeod C, Yuan G, Vernon SW. Colorectal cancer screening by 
primary care physicians: recommendations and practices, 2006–2007. Am. J. Prev. Med. 2009; 
37(1):8–16. [PubMed: 19442479] 
Miller et al. Page 8













Lester WT, Ashburner JM, Grant RW, Chueh HC, Barry MJ, Atlas SJ. Mammography FastTrack: an 
intervention to facilitate reminders for breast cancer screening across a heterogeneous multi-clinic 
primary care network. J. Am. Med. Inform. Assoc. 2009; 16(2):187–195. [PubMed: 19074304] 
Meissner HI, Tiro JA, Yabroff KR, Haggstrom DA, Coughlin SS. Too much of a good thing? 
Physician practices and patient willingness for less frequent Pap test screening intervals. Med. 
Care. 2010; 48(3):249–259. [PubMed: 20182268] 
Meissner HI, Klabunde CN, Han PK, Benard VB, Breen N. Breast cancer screening beliefs, 
recommendations and practices. Cancer. 2011; 117(14):3101–3111. [PubMed: 21246531] 
Nadel MR, Shapiro JA, Klabunde CN, et al. A national survey of primary care physicians' methods for 
screening for fecal occult blood. Ann. Intern. Med. 2005; 142(2):86–94. [PubMed: 15657156] 
Nadel MR, Berkowitz Z, Klabunde CN, Smith RA, Coughlin SS, White MC. Fecal occult blood 
testing beliefs and practices of U.S. primary care physicians: serious deviations from evidence-
based recommendations. J. Gen. Intern. Med. 2010; 25(8):833–839. [PubMed: 20383599] 
Najem GR, Batuman F, Smith AM. Papanicolaou test status among inner-city adolescent girls. Am. J. 
Prev. Med. 1996; 12(6):482–486. [PubMed: 8955780] 
Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. U.S. Preventive Services Task 
Force (USPSTF). Screening for breast cancer: an update for the U.S. Preventive Services Task 
Force. Ann. Intern. Med. 2009; 151(10):727–737. (W237–42). [PubMed: 19920273] 
Nichols C, Holt CL, Shipp M, Eloubeidi M, Fouad MN, Britt K. Physician knowledge, perceptions of 
barriers, and patient colorectal cancer screening practices. Am. J. Med. Qual. 2009; 24(2):116–
122. [PubMed: 19233946] 
Palmer RC, Chhabra D, McKinney S. Colorectal cancer screening adherence in African-American 
men and women 50 years of age and older living in Maryland. J. Community Health. 2010 Nov 
24. http://dx.doi.org/10.1007/s10900-010-9336-4. 
Pellegrino ED, Relman AS. Professional medical associations: ethical and practical guidelines. JAMA. 
1999; 282(10):984–986. [PubMed: 10485685] 
Ramirez AG, Wildes KA, Napoles-Springer A, Perez-Stable E, Talavera G, Rios E. Physician gender 
differences in general and cancer-specific prevention attitudes and practices. J. Cancer Educ. 2009; 
24(2):85–93. [PubMed: 19431022] 
Rauscher GH, Hawley ST, Earp JA. Baseline predictors of initiation vs. maintenance of regular 
mammography use among rural women. Prev. Med. 2005; 40(6):822–830. [PubMed: 15850884] 
Ryerson AB, Eheman C, Burton J, et al. Symptoms, diagnoses, and time to key diagnostic procedures 
among older U.S. women with ovarian cancer. Obstet. Gynecol. 2007; 109(5):1053–1061. 
[PubMed: 17470582] 
Saraiya M, Berkowitz Z, Yabroff KR, Wideroff L, Kobrin S, Benard V. Cervical cancer screening 
with both human papillomavirus and Papanicolaou testing vs Papanicolaou testing alone: what 
screening intervals are physicians recommending? Arch. Intern. Med. 2010; 170(11):977–985. 
[PubMed: 20548011] 
Schueler KM, Chu PW, Smith-Bindman R. Factors associated with mammography utilization: a 
systematic quantitative review of the literature. J. Women's Health (Larchmt). 2008; 17(9):1477–
1498. [PubMed: 18954237] 
Sequist TD, Zaslavsky AM, Marshall R, Fletcher RH, Ayanian JZ. Patient and physician reminders to 
promote colorectal cancer screening: a randomized controlled trial. Arch. Intern. Med. 2009; 
169(4):364–371. [PubMed: 19237720] 
Smith RA, Cokkinides V, Brooks D, Saslow D, Shah M, Brawley OW. Cancer screening in the United 
States, 2011: A review of current American Cancer Society guidelines and issues in cancer 
screening. CA Cancer J. Clin. 2011; 61:8–30. [PubMed: 21205832] 
Teng EJ, Friedman LC, Green CE. Determinants of colorectal cancer screening behavior among 
Chinese Americans. Psychooncology. 2006; 15(5):374–381. [PubMed: 16143960] 
Trivers KF, Baldwin LM, Miller JW, et al. Reported referral for genetic counseling or BRCA 1/2 
testing among us physicians. Cancer. 2011; 117(23):5334–5343. [PubMed: 21792861] 
Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006; 
24(Suppl. 1):S4–S15.
Miller et al. Page 9













U.S. Preventive Services Task Force. Screening for ovarian cancer: recommendation statement. 2004 
May. http://www.uspreventiveservicestaskforce.org/3rduspstf/ovariancan/ovcanrs.htm. 
U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. preventive services task 
force recommendation statement. Ann. Intern. Med. 2008; 149(9):627–637. [PubMed: 18838716] 
U.S. Preventive Services Task Force (USPSTF). Screening for cervical cancer: recommendations and 
rationale, Update to 1996 Guide to Clinical Preventive Services. 2nd ed.1996. http://
www.ahrq.gov/clinic/3rduspstf/cervcan/cervcanrr.htm.
Werny DM, Saraiya M, Carrera J, Coughlin SS, Frank E. Learning amid controversy: prostate cancer 
knowledge and screening practices among US medical students. J. Cancer Educ. 2008; 23(2):108–
113. [PubMed: 18569246] 
Wong C, Berkowitz Z, Saraiya M, Wideroff L, Benard VB. US physicians' intentions regarding impact 
of human papillomavirus vaccine on cervical cancer screening. Sex. Health. 2010; 7(3):338–345. 
[PubMed: 20719225] 
Yabroff KR, Klabunde CN, Yuan G, et al. Are physicians' recommendations for colorectal cancer 
screening guideline-consistent? J. Gen. Intern. Med. 2011a; 26(2):177–184. [PubMed: 20949328] 
Yabroff R, Zapka J, Klabunde C, et al. Systems strategies to support cancer screening in U.S. primary 
care practice. Cancer Epidemiol. Biomarkers Prev. 2011b; 20(12):2471–2479. [PubMed: 
21976292] 
Miller et al. Page 10

























Miller et al. Page 11
Table 1
Characteristics of physician respondents and their practices.




  Family medicine 41.5
  Internal medicine 41.0
  Obstetrics–Gynecology 17.5
Age
  30–39 years 23.0
  30–39 years 34.3
  50–64 years 42.7
Race
  Caucasian 71.1
  Asian/Pacific Islander 16.0
  African American 5.1





  0–10 years 17.9
  11–20 years 37.4
  21+ years 44.6
Primary setting
  Office practice or freestanding clinic 78.8
  Urgicenter 1.7
  Hospital outpatient department 5.8
  Health maintenance organization or other prepaid practice 2.5
  Community health center 3.6
  Federal government-operated clinic 2.7
  Other, including institutional setting, non-federal government clinic, family planning clinic, and tribal health center/Indian 
Health Service or missing
4.8
Practice type
  Solo practice 23.3
  Single-specialty group 42.8
  Multi-specialty group 27.9
  Other or missing 5.9
Weekly average number of patients
  1–60 27.5
  61–90 28.8
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Physician and practice characteristics All physicians
N = 1574
Weighted %
  91+ 43.6
Involved in clinical teaching 40.4
Personal experience with cancer
  Family (immediate or extended) 78.7
  Self 4.8
  None 16.5
Geographic location
  Urban 84.6
  Large rural 9.3
  Small/remote rural 6.1
Census division
  New England 5.6
  Middle Atlantic 14.1
  East North Central 16.5
  West North Central 8.0
  South Atlantic 16.3
  East South Central 5.5
  West South Central 9.2
  Mountain 6.9
  Pacific 18.0
Level of risk taking
  Low 58.3
  Medium 34.1
  High 7.6
Fear of malpractice
  Low 14.1
  Medium 28.0
  High 57.9
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Table 2
Organizations reported to influence physician cancer screening recommendations by specialty type.
Organizations Family medicine physicians Obstetrics/gynecology physicians Internal medicine physicians
% % %
Physician specialty organizations
American Academy of Family 
Physicians (AAFP)*
86.9 2.0 8.4
American College of Obstetricians and 
Gynecologists (ACOG)*
24.4 96.8 9.4
American College of Physicians/
American Society of Internal Medicine 
(ACP/ASIM)*
4.3 1.6 71.9




American Medical Association 
(AMA)*
8.9 17.1 21.2
American Cancer Society (ACS)* 60.4 73.7 67.2
National Institutes of Health (NIH)/
National Cancer Institute (NCI)*
27.1 47.0 34.6
U.S. Preventive Services Task Force 
(USPSTF)*
64.2 27.7 54.1
Local institution (for example, HMO) 3.6 4.3 4.2
Note: Columns do not sum to 100% because physicians could choose three organizations.
*
P ≤ 0.001 for chi-square test across the rows.
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Table 3
Physicians' level of agreement on the effectiveness of various tests for breast, cervical, ovarian and colorectal 






% % % %
Breast cancer
Mammography for 40–49 year olds 50.6 44.0 4.6 0.8
Mammography for 50–69 year olds 81.7 17.6 0.3 0.3
Clinical breast exam 40.0 45.4 12.6 2.0
Magnetic resonance imaging (MRI) 7.8 26.6 7.0 18.6
Cervical cancer
Human papillomavirus (HPV) test without Papanicolauo (Pap) test for 30–65 year olds (primary 
screening, not reflexive)
13.5 34.5 40.2 11.7
Pap test for 21–65 year olds 70.3 29.1 0.4 0.2
Ovarian cancer
Cancer antigen CA-125 3.8 13.8 47.5 34.9
Transvaginal ultrasound 5.9 24.4 46.1 23.5
Annual pelvic exam 30.0 39.1 23.3 7.6
Colorectal cancer (for those 50 years and older)
Colonoscopy 81.8 17.2 0.7 0.2
Computed tomography (CT) colonography 5.6 32.0 48.2 14.2
Sigmoidoscopy 10.1 36.8 38.9 14.1
Stool card for occult blood (3-day take-home FOBT) 24.0 47.1 23.7 5.2
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Table 4
Factors significantly associated with agreement in the clinical effectiveness of cancer screening tests among 






Mammography for 40–49 year olds
  USPSTF a top influential organization (yes vs. no) 0.96 0.94, 0.99
  ACS a top influential organization (yes vs. no) 1.04 1.01, 1.07
Mammography for 50–69 year olds
  Personal experience with cancer vs. none 0.51 0.49, 0.53
  Clinical breast exam
  USPSTF a top influential organization (yes vs. no) 0.88 0.84, 0.92
  Involved in clinical teaching (yes vs. no) 0.93 0.89, 0.98
Cervical cancer
HPV test for 30–65 year olds without Pap test
  Family medicine vs. obstetrics/gynecology 0.73 0.65, 0.82
  Internal medicine vs. obstetrics/gynecology 0.87 0.77, 0.99
Pap test for 21–65 year olds
  ACS a top influential organization (yes vs. no) 1.02 1.01, 1.03
Ovarian cancer
Cancer Antigen CA-125
  Personal experience with cancer vs. none 0.37 0.17, 0.78
  USPSTF a top influential organization (yes vs. no) 0.44 0.33, 0.57
  Board Certified (yes vs. no) 0.63 0.46, 0.88
  Group practice vs. solo practice 0.67 0.52, 0.86
  ≥20 years in practice vs. ≤10 years 1.18 1.03, 1.36
  ≥30 years in practice vs. ≤10 years 1.39 1.07, 1.80
  ≥40 years in practice vs. ≤10 years 1.61 1.11, 2.35
  Family medicine vs. obstetrics/gynecology 2.45 1.79, 3.35
  Internal medicine vs. obstetrics/gynecology 2.82 2.06, 3.86
Transvaginal ultrasound
  USPSTF a top influential organization (yes vs. no) 0.63 0.52, 0.76
  Board certified (yes vs. no) 0.76 0.59, 0.98
  Group practice vs. Solo practice 0.71 0.59, 0.85
  Personal risk taking low vs. medium 0.67 0.47, 0.97
  Personal risk taking high vs. medium 0.81 0.67, 0.97
  NIH/NCI one of top three influential organizations (yes vs. no) 1.30 1.09, 1.54
  Internal medicine vs. obstetrics/gynecology 1.27 1.04, 1.55
  ≥20 years in practice vs. ≤10 years 1.17 1.06, 1.29
  ≥30 years in practice vs. ≤10 years 1.36 1.13, 1.64
  ≥40 years in practice vs. ≤10 years 1.56 1.20, 2.02
Pelvic exam


















  USPSTF a top influential organization (yes vs. no) 0.76 0.71, 0.82
  Group practice vs. Solo practice 0.86 0.80, 0.93
  Involved in clinical teaching (yes vs. no) 0.90 0.84, 0.97
  Internal medicine vs. obstetrics/gynecology 1.13 1.03, 1.24
  Family medicine vs. obstetrics/gynecology 1.14 1.05, 1.25
Colorectal cancer
Flexible sigmoidoscopy
  Internal medicine vs. obstetrics/gynecology 0.85 0.74, 0.97
  USPSTF a top influential organization (yes vs. no) 1.24 1.10, 1.40
  Pacific vs. New England 1.48 1.09, 2.01
Fecal occult blood testing
  Middle Atlantic vs. New England 1.27 1.04, 1.54
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